SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein

Por um escritor misterioso

Descrição

Abstract Pilomatricomas are benign tumors originating from the capillary matrix, which may
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Real‐World Evidence for the NINLARO® (ixazomib) Regimen
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
JCM, Free Full-Text
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
The mutagenic impact of melphalan in multiple myeloma
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Frontiers SDHB exon 1 deletion: A recurrent germline mutation in Colombian patients with pheochromocytomas and paragangliomas
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Cellular, molecular, and therapeutic characterization of pilocarpine-induced temporal lobe epilepsy
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide
SciELO - Brasil - Multiple pilomatricomas in twins with Rubinstein
Publications: MPI-CBG
de por adulto (o preço varia de acordo com o tamanho do grupo)